Human Genome Sciences Inc., a GSK Company

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Human Genome Sciences Inc., a GSK Company sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed later-stage tilt top decile by trial count

Human Genome Sciences Inc., a GSK Company: 9 sponsored US clinical trials, none currently recruiting.

Human Genome Sciences Inc., a GSK Company sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 6 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Nephritis, with 1 trials.

Top-decile sponsor footprint

Human Genome Sciences Inc., a GSK Company ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 3

Belimumab in Remission of VASculitis

NCT01663623
COMPLETED Phase 4

Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)

NCT01632241
COMPLETED Phase 3

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

NCT01639339
COMPLETED Phase 4

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492
COMPLETED Phase 3

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496
COMPLETED Phase 1

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
COMPLETED Phase 3

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

NCT00724867
COMPLETED Phase 1

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT00712855
COMPLETED Phase 2

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

NCT00583362

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 4
Phase 4 2

Therapeutic Areas

Lupus Nephritis 1
Systemic Lupus Erythematosus 1

How the Human Genome Sciences Inc., a GSK Company archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 6 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Lupus Nephritis (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Human Genome Sciences Inc., a GSK Company: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Human Genome Sciences Inc., a GSK Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Human Genome Sciences Inc., a GSK Company4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Human Genome Sciences Inc., a GSK Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Human Genome Sciences Inc., a GSK Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Human Genome Sciences Inc., a GSK Company page

9 registered trials is a research-attention snapshot, not an endorsement of Human Genome Sciences Inc., a GSK Company or any single study.

  • None of Human Genome Sciences Inc., a GSK Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lupus Nephritis is the condition Human Genome Sciences Inc., a GSK Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Nephritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Human Genome Sciences Inc., a GSK Company pipeline card: 9 registered trials from official public datasets.Report a data error.